Abivax (ABVX) Announces $150M ATM Program

Go back to Abivax (ABVX) Announces $150M ATM Program

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

November 19, 2024 4:30 PM UTC

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

PARIS, France, November 19, 2024 10:30PM CET Abivax SA (Euronext Paris: FR0012333284 ABVX / Nasdaq - ABVX) (Abivax or the Company), a clinical-stage biotechnology company focused on developing therapeutics that harness the bodys natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced the implementation of an At-The-Market program (ATM Program) allowing the Company to issue and sell, including with unsolicited investors who have expressed an interest, ordinary shares in... More